Armata Pharmaceuticals (ARMP) Non-Current Deferred Tax Liability (2013 - 2026)

Armata Pharmaceuticals has reported Non-Current Deferred Tax Liability for 14 years, with the latest figure at $3.1 million in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability changed 0.0% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (changed 0.0% YoY) and the FY2025 annual result came in at $3.1 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $3.1 million in Q1 2026 per ARMP's latest filing, from $3.1 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $3.1 million in Q1 2022 and troughed at $3.1 million in Q1 2022.
• A 5-year average of $3.1 million and a median of $3.1 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• The widest YoY moves for Non-Current Deferred Tax Liability: up 0.0% in 2022, down 0.0% in 2022.
• Over 5 years, Non-Current Deferred Tax Liability stood at $3.1 million in 2022, then changed by 0.0% to $3.1 million in 2023, then changed by 0.0% to $3.1 million in 2024, then changed by 0.0% to $3.1 million in 2025, then changed by 0.0% to $3.1 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $3.1 million, $3.1 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.